ArticleNanomedicine : nanotechnology, biology, and medicine2013
Ultrabright fluorescent mesoporous silica nanoparticles for prescreening of cervical cancer.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Dissecting oral premalignant carcinogenesis: spatial omics mechanisms and nanomedicine-driven therapeutic innovation.Molecular cancer · 2026Review
- Innovations in Biosensing Technologies for Cancer Diagnosis and Theranostics.Mini reviews in medicinal chemistry · 2026Review
- Glutathione-responsive folic acid modified fluorescent SBA-15 nanocarrier for simultaneous imaging and drug delivery in prostate cancer treatment.Journal of materials science. Materials in medicine · 2025Article
- Long-Term Cell-Membrane-Coated Ultrabright Nanospheres for Targeted Cancer Cell Imaging and Hydrophobic Drug Delivery.Chemistry of materials : a publication of the American Chemical Society · 2025Article
- Recent Advances in HPV Detection: From Traditional Methods to Nanotechnology and the Application of Quantum Dots.International journal of nanomedicine · 2025Review
- Ultrabright fluorescent particlesNanoscale · 2024Review
- Nanotechnological Advances in the Diagnosis of Gynecological Cancers and Nanotheranostics.Current pharmaceutical design · 2024Review
- Towards the Use of Individual Fluorescent Nanoparticles as Ratiometric Sensors: Spectral Robustness of Ultrabright Nanoporous Silica Nanoparticles.Sensors (Basel, Switzerland) · 2023Article
- Fluorescent silica nanoparticles as an internal marker in fruit flies and their effects on survivorship and fertility.Scientific reports · 2022Article
- Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy.Frontiers in pharmacology · 2022Review
- An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine.Pharmaceutics · 2021Review
- Zebrafish Models for the Safety and Therapeutic Testing of Nanoparticles with a Focus on Macrophages.Nanomaterials (Basel, Switzerland) · 2021Review
- Recent Trends in Morphology-Controlled Synthesis and Application of Mesoporous Silica Nanoparticles.Nanomaterials (Basel, Switzerland) · 2020Review
- Ultrabright Fluorescent Silica Nanoparticles for Multiplexed Detection.Nanomaterials (Basel, Switzerland) · 2020Article
- In Vivo Targeting of Xenografted Human Cancer Cells with Functionalized Fluorescent Silica Nanoparticles in Zebrafish.Journal of visualized experiments : JoVE · 2020Article
- Ultrabright fluorescent silica nanoparticles for in vivo targeting of xenografted human tumors and cancer cells in zebrafish.Nanoscale · 2019Article
- Nanomedicine applications in women's health: state of the art.International journal of nanomedicine · 2018Review
- An special epithelial staining agents: folic acid receptor-mediated diagnosis (FRD) effectively and conveniently screen patients with cervical cancer.International journal of clinical and experimental medicine · 2015Article
- Ultrabright NIR fluorescent mesoporous silica nanoparticles.Journal of materials chemistry. B · 2014Article
- Ultrabright fluorescent mesoporous silica nanoparticles for prescreening of cervical cancer.Nanomedicine : nanotechnology, biology, and medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We report on the first functional use of recently introduced ultrabright fluorescent mesoporous silica nanoparticles, which are functionalized with folic acid, to distinguish cancerous and precancerous cervical epithelial cells from normal cells. The high brightness of the particles is advantageous for fast and reliable identification of both precancerous and cancerous cells. Normal and cancer cells were isolated from three healthy women and three cancer patients. Three precancerous cell lines were derived by immortalization of primary cultures of normal cells with human papillomavirus type-16 (HPV-16) DNA. We observed substantially different particle internalization by normal and cancerous/precancerous cells after a short incubation time of 15 minutes. Compared to HPV-DNA and cell pathology tests, which are currently used for prescreening of cervical cancer, we demonstrated that the specificity of our method was similar (94-95%), whereas its sensitivity was significantly better (95-97%) than the sensitivity of those currently used tests (30-80%). FROM THE CLINICAL EDITOR: This team of investigators reports on the development of a new screening test for cervical cancer using ultrabright fluorescent mesoporous silica nanoparticles functionalized with folic acid, enabling significantly better sensitivity (95-97% vs. 30-80%) and maintained specificity (94-95%) compared with current clinical tests. This test should find a way to clinical use in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.